HALO (Halozyme Therapeutics) Ending Cash Position: $164 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HALO Halozyme Therapeutics Inc HALO
91 GF Score
Price $100.11
GF Value $96.91
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Halozyme Therapeutics Ending Cash Position?

Halozyme Therapeutics HALO -1.67% 91 Ending Cash Position is $164 Mil as of Jun. 2026. GuruFocus rates HALO with a GF Score™ of 91/100 and a GF Value™ of $96.91 (Fairly Valued). The stock has 4 warning signs investors should review.

Halozyme Therapeutics's Ending Cash Position for the quarter that ended in Jun. 2026 was $164 Mil.

Halozyme Therapeutics's quarterly Ending Cash Position increased from Dec. 2025 ($136 Mil) to Mar. 2026 ($312 Mil) but then declined from Mar. 2026 ($312 Mil) to Jun. 2026 ($164 Mil).

Halozyme Therapeutics's annual Ending Cash Position declined from Dec. 2023 ($118 Mil) to Dec. 2024 ($116 Mil) but then increased from Dec. 2024 ($116 Mil) to Dec. 2025 ($136 Mil).

Halozyme Therapeutics Ending Cash Position Related Terms

Halozyme Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Halozyme Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halozyme Therapeutics Ending Cash Position Chart

Halozyme Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 119.22 234.70 118.37 115.85 136.42

Halozyme Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 61.86 419.67 136.42 312.01 163.99
HALO
91GF Score
Halozyme Therapeutics Inc HALO
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Halozyme Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Halozyme Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=115.85+20.571
=136

Halozyme Therapeutics's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=312.009+-148.023
=164

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $164 Mil mean?
Halozyme Therapeutics (HALO) has a Ending Cash Position of $164 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Halozyme Therapeutics and its competitors.
Is Halozyme Therapeutics' Ending Cash Position too high?
Halozyme Therapeutics' current Ending Cash Position is $164 Mil. Overall, Halozyme Therapeutics has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' Ending Cash Position compare to NUVL and KRYS?
Halozyme Therapeutics' Ending Cash Position of $164 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Halozyme Therapeutics and its competitors. Halozyme Therapeutics's current Ending Cash Position is $164 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (HALO) is currently considered Fairly Valued. The stock's GF Value™ is $96.91, compared to a current price of $100.11 — trading 3.3% above its estimated fair value. The current Ending Cash Position is $164 Mil. Halozyme Therapeutics' overall GF Score™ is 91/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Halozyme Therapeutics (HALO), the current Ending Cash Position is $164 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Halozyme Therapeutics (HALO) Overvalued in 2026?

Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be overvalued. The current stock price of $100.11 is trading 3.3% above its estimated GF Value™ of $96.91. GuruFocus considers Halozyme Therapeutics to be Fairly Valued.

Key valuation signals for HALO:

  • Ending Cash Position: $164 Mil
  • GF Value™: $96.91 vs. price of $100.11 (3.3% above fair value)
  • GF Score™: 91/100 with 4 warning signs

No single metric tells the full story. See the HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Halozyme Therapeutics Business Description

Address 12390 El Camino Real, San Diego, CA, USA, 92130
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
91GF Score

Get the complete analysis for HALO

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$100.11
Price
$96.91
GF Value